It has long been the dream of humanity to regain youth and defeat aging. Research tried for decades to explore the mechanisms of aging and possible ways to intervene therapeutically in order to delay/prevent aging. Senescence is one of the processes by which aging cells can invoke deleterious effects on other cells and remote organs. Cellular senescence could be the missing link between aging and related chronic diseases including diabetes and cardiovascular diseases. Senescent cells are in a state of cell cycle arrest but remain metabolically active by secreting inflammatory factors. In this mini-review, we summarize current knowledge on cellular senescence and its secretory phenotype and their mechanistic role, that may help identify potential drug targets for age-related diseases, and treating them as a group, rather than one at a time thereby facilitating healthful life span extension in humans.

Keywords: Senescence; Diabetes; Cardiovascular Diseases

References

1. Tamara Tchkonia., et al. “Cellular senescence and the senescent secretory phenotype: therapeutic opportunities”. Journal of Clinical Investigation 123.3 (2013): 966-972. 
2. Rafael de Cabo., et al. “Effects of Intermittent Fasting on Health, Aging, and Disease”. New England Journal of Medicine 381.26 (2019): 2541-2551.
3. Kapahi P., et al. “With TOR, Less Is More: A Key Role for the Conserved Nutrient-Sensing TOR Pathway in Aging”. Cell Metabolism 11.6 (2010): 453-465. 
4. Olshansky SJ., et al. “In search of Methuselah: estimating the upper limits to human longevity”. Science 250.4981 (1990): 634-640.
5. Demaria M., et al. “An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA”. Developmental Cell 31.6 (2014): 722-733. 
6. Jun J-I and Lau LF. “The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing”. Nature Cell Biology 12.7 (2010): 676-685. 
7. Muñoz-Espín D., et al. “Programmed cell senescence during mammalian embryonic development”. Cell 155.5 (2013): 1104-1118.
8. Hadis S., et al. “Cellular senescence links aging and diabetes in cardiovascular disease”. American Journal of Physics 315.3 (2018): 448-462.
9. RISE Consortium. “Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp”. Diabetes Care 41.8 (2018): 1696-1706. 
10. Gu J., et al. “Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis”. Cell Death and Disease 9.2 (2018): 82. 
11. Katsuumi G., et al. “Vascular senescence in cardiovascular and metabolic diseases”. Frontiers in Cardiovascular Medicine 5 (2018): 18. 
12. Fiordaliso F., et al. “Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death”. Diabetes 50.10 (2001): 2363-2375. 
13. Shakeri H., et al. “Neuregulin-1 attenuates stress-induced vascular senescence”. Cardiovascular Research 114.7 (2018): 1041-1051. 
14. Matsushita H., et al. “eNOS activity is reduced in senescent human endothelial cells: Preservation by hTERT immortalization”. Circulation Research 89.8 (2001): 793-798. 
15. Gevaert AB., et al. “Endothelial senescence contributes to heart failure with preserved ejection fraction in an aging mouse model”. Circulation: Heart Failure 10.6 (2017): e003806. 
16. Lakatta EG. “So! What’s aging? Is cardiovascular aging a disease?” Journal of Molecular and Cellular Cardiology 83 (2015): 1-13. 
17. Palmer and Associates. “Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity”. Diabetes 64.7 (2015): 2289-2298.
18. Moiseeva O., et al. “Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-kB activation”. Aging Cell 12.3 (2013): 489-498.
19. Minamino T., et al. “Akt-induced cellular senescence: implication for human disease”. Cell Cycle 3.4 (2004): 449-451.
20. LJ Hickson., et al. “Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease”. EBioMedicine 47 (2019): 446-456.
21. Yabing Xiong and Lili Zhou. “The Signaling of Cellular Senescence in Diabetic Nephropathy”. Oxidative Medicine and Cellular Longevity (2019): 7495629.
22. N Tasdemir., et al. “BRD4 connects enhancer remodeling to senescence immune surveillance”. Cancer Discovery 6.6 (2016): 612-629.
23. Peter J., et al. “Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes”. Cell Metabolism 29.5 (2019): 1045-1060.
24. Palmer K., et al. “Targeting senescent cells alleviates obesity‐induced metabolic dysfunction”. Aging Cell 18.3 (2019): e12950. 
25. Ogrodnik., et al. “Cellular senescence drives age-dependent hepatic steatosis”. Nature Communications 8 (2017): 15691. 
26. Roos M., et al. “Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice”. Aging Cell 15.5 (2016): 973-977. 
27. Yi Zhu., et al. “New agents that target senescent cells: the flavone, fisetin, and the BCL‐XL inhibitors, A1331852 and A1155463”. Aging 9.3 (2017): 955-963.
28. Stroissnigg HF., et al. “Identification of HSP90 inhibitors as a novel class of senolytics”. Nature Communications 8.1 (2017): 422.
29. Malavolta M., et al. “Inducers of Senescence, Toxic Compounds, and Senolytics: The Multiple Faces of Nrf2-Activating Phytochemicals in Cancer Adjuvant Therapy”. Mediators of Inflammation (2018): 4159013.